WAVE Life Sciences Ltd. (NASDAQ:WVE – Get Free Report) Director Ken Takanashi sold 3,864 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $6.01, for a total transaction of $23,222.64. Following the completion of the transaction, the director directly owned 20,079 shares of the company’s stock, valued at approximately $120,674.79. The trade was a 16.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
WAVE Life Sciences Trading Down 0.8%
WAVE Life Sciences stock traded down $0.04 during trading hours on Thursday, hitting $5.20. 6,048,504 shares of the stock traded hands, compared to its average volume of 2,757,944. The firm’s 50-day moving average price is $5.88 and its two-hundred day moving average price is $8.42. The company has a market cap of $1.02 billion, a PE ratio of -4.77 and a beta of -1.26. WAVE Life Sciences Ltd. has a one year low of $5.01 and a one year high of $21.73.
WAVE Life Sciences (NASDAQ:WVE – Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04). WAVE Life Sciences had a negative return on equity of 50.36% and a negative net margin of 309.73%.The firm had revenue of $2.27 million for the quarter, compared to analysts’ expectations of $7.45 million. On average, sell-side analysts expect that WAVE Life Sciences Ltd. will post -1.12 earnings per share for the current fiscal year.
Institutional Trading of WAVE Life Sciences
Analyst Upgrades and Downgrades
WVE has been the subject of a number of research reports. Citigroup decreased their price objective on WAVE Life Sciences from $24.00 to $19.00 and set a “buy” rating for the company in a report on Friday, July 31st. New Street Research set a $13.00 target price on shares of WAVE Life Sciences in a research report on Thursday, June 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of WAVE Life Sciences in a research note on Friday, July 17th. Mizuho lowered their target price on shares of WAVE Life Sciences from $27.00 to $23.00 and set an “outperform” rating for the company in a report on Tuesday, August 4th. Finally, Wells Fargo & Company boosted their price target on WAVE Life Sciences from $13.00 to $14.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.53.
Check Out Our Latest Report on WVE
WAVE Life Sciences Company Profile
WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.
The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.
Read More
- Five stocks we like better than WAVE Life Sciences
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for WAVE Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
